Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib

NCT04486833 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

158

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Non-Small Cell Lung

Interventions

BIOLOGICAL: quaratusugene ozeplasmid
DRUG: osimertinib
DRUG: Platinum-Based Chemotherapy

Sponsor

Genprex, Inc.